Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Cash from Operations (2023 - 2025)

Historic Cash from Operations for Immunome (IMNM) over the last 3 years, with Q3 2025 value amounting to -$40.5 million.

  • Immunome's Cash from Operations fell 1856.47% to -$40.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$185.0 million, marking a year-over-year decrease of 11466.48%. This contributed to the annual value of -$110.8 million for FY2024, which is 136397.99% down from last year.
  • Latest data reveals that Immunome reported Cash from Operations of -$40.5 million as of Q3 2025, which was down 1856.47% from -$49.4 million recorded in Q2 2025.
  • Immunome's 5-year Cash from Operations high stood at $24.2 million for Q1 2023, and its period low was -$53.1 million during Q1 2025.
  • Moreover, its 3-year median value for Cash from Operations was -$23.4 million (2024), whereas its average is -$23.8 million.
  • The largest annual percentage gain for Immunome's Cash from Operations in the last 5 years was 1856.47% (2025), contrasted with its biggest fall of 37497.76% (2025).
  • Immunome's Cash from Operations (Quarter) stood at -$17.5 million in 2023, then tumbled by 140.91% to -$42.1 million in 2024, then grew by 3.69% to -$40.5 million in 2025.
  • Its last three reported values are -$40.5 million in Q3 2025, -$49.4 million for Q2 2025, and -$53.1 million during Q1 2025.